Floatz logo

Induced pluripotent stem cells (iPSCs)

Epilepsy, Generalized

University of Missouri-ColumbiaCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Epilepsy, Generalized cohort.

Asset / SponsorPhaseRating
Topamax
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
MELATONIN
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BB
Clobazam
Lundbeck LLC
Phase 3BB
Cenobamate
Ono Pharmaceutical Co., Ltd.
Phase 3BB
Diazepam
Pfizer
Phase 3B

View all 11 →

Same molecule, other indications

Induced pluripotent stem cells (iPSCs) is also rated in:

ataxia telangiectasiaDormant
D
Indicative ·
30 / 100
View asset →
rareDormant
D
Indicative ·
30 / 100
View asset →
global developmental delay with or without impaired intellectual developmentDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →